Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

Cruz, Francisco; Herschorn, Sender; Aliotta, Philip J.; Brin, Mitchell F.; Thompson, Catherine; Lam, Wayne; Daniell, Grace; Heesakkers, John; Haag‐Molkenteller, Cornelia

doi:10.1016/j.eururo.2011.07.002

Cited by 415 publications

(494 citation statements)

References 23 publications

Supporting

Mentioning

445

Contrasting

Unclassified

Order By: Relevance

“…In another study, among 39 patients with HAM/TSP who had received pulse therapy with methylprednisolone, improvement in motor disability was observed in more than 60% of cases, but no improvements in bladder dysfunction were noted 10 . Botulinum toxin A is a neuromuscular blocking agent that can promote weakness in the detrusor sphincter muscle and control symptoms of OAB, and has been used to treat idiopathic and neurogenic detrusor overactivity in patients with multiple sclerosis, spinal cord injury, and children with OAB due to myelomeningocele 11,12 . In a double-blind clinical trial of multiple sclerosis patients, botulinum toxin A was not only more effective than placebo, but 60% of the patients who had received botulinum toxin A had no urinary loss for up to 12 weeks 11 .…”

mentioning

confidence: 99%

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

Neto

Bittencourt

Oliveira

et al. 2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfi ll criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced signifi cantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.

show abstract

mentioning

confidence: 99%

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

Neto

Bittencourt

Oliveira

et al. 2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…[9][10][11] We were able to make a number of associations regarding the presence of coexisting symptoms. For women with II alone, when a cause of incontinence was demonstrated, USUI was found in 81% of women.…”

Section: Discussionmentioning

confidence: 99%

Urodynamic findings in women with insensible incontinence

et al. 2012

View full text Add to dashboard Cite

Abbreviations & AcronymsObjectives: To define the urodynamic study findings among women with insensible urinary incontinence. Methods: Women complaining of insensible incontinence who underwent urodynamics at our center were identified. Coexisting symptoms of stress incontinence, urgency incontinence and/or mixed incontinence were recorded. The primary outcome was the urodynamic study finding. Urodynamic stress incontinence, detrusor overactivity incontinence, combination of both or neither (no incontinence) were the possible diagnoses. Results: A total of 58% of patients had insensible incontinence alone and 42% had insensible incontinence combined with other urinary incontinence symptoms. Of the patients with insensible incontinence alone, 37% had no incontinence on urodynamics, whereas urodynamic stress incontinence was diagnosed in 52%. Isolated urodynamic stress incontinence was found in 73% of patients with insensible and stress incontinence symptoms. In patients with insensible plus urgency incontinence, isolated detrusor overactivity incontinence and detrusor overactivity incontinence with urodynamic stress incontinence were found in the same percentage of women (40% each). In patients with symptoms including stress urinary incontinence, stress incontinence was the predominant urodynamic finding. Conclusions:In patients who have incontinence symptoms in addition to insensible incontinence, these symptoms are highly predictive of urodynamic findings. In particular, women with insensible incontinence, concomitant stress incontinence symptoms are most predictive of urodynamic findings (i.e. urodynamic stress urinary incontinence). In contrast, where insensible incontinence represents the only symptom, urodynamic findings vary widely, with a significant proportion having non-diagnostic studies.

show abstract

“…Botulinum toxin A has also been examined among patients with neurologic problems (mixed populations of MS and spinal cord injury). [8][9][10] In these studies, more than half the patients treated experienced significant improvement in symptoms. Indeed, as many as 76% of patients in one trial achieved complete continence.…”

Section: A Urological Challenge: Voiding Dysfunction In Multiple Sclementioning

confidence: 98%

A urological challenge: Voiding dysfunction in multiple sclerosis

Corcos¹

2013

CUAJ

View full text Add to dashboard Cite

Patients with multiple sclerosis (MS) have a very high prevalence of lower urinary tract symptoms—as many as 90% of patients with MS experience some form of voiding dysfunction and/or incontinence.1 This summary provides a brief overview of MS epidemiology, pathophysiology, the impact of the disease on patient quality of life, and the particular kinds of urinary tract abnormalities and symptoms that can present among patients with MS. Strategies to help diminish the impact of these symptoms are also discussed.

show abstract

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

Cited by 415 publications

References 23 publications

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

Urodynamic findings in women with insensible incontinence

A urological challenge: Voiding dysfunction in multiple sclerosis

Contact Info

Product

Resources

About